Bicycle Therapeutics/$BCYC
1D1W1MYTD1Y5YMAX
Capital at risk
About Bicycle Therapeutics
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.
- Ticker
- $BCYC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 288
- Headquarters
- Cambridge, United Kingdom
- Website
- www.bicycletherapeutics.com
BCYC Metrics
BasicAdvanced
$270M
-
-$2.74
1.53
-
Price and volume
Market cap
$270M
Beta
1.53
52-week high
$9.16
52-week low
$3.75
Average daily volume
349K
Financial strength
Current ratio
12.076
Quick ratio
11.703
Long term debt to equity
2.681
Total debt to equity
2.873
Interest coverage (TTM)
-1,067.88%
Profitability
EBITDA (TTM)
-200.812
Gross margin (TTM)
-208.89%
Net profit margin (TTM)
-311.11%
Operating margin (TTM)
-336.74%
Effective tax rate (TTM)
-0.92%
Revenue per employee (TTM)
$210,000
Management effectiveness
Return on assets (TTM)
-17.91%
Return on equity (TTM)
-32.30%
Valuation
Price to revenue (TTM)
4.386
Price to book
0.53
Price to tangible book (TTM)
0.53
Price to free cash flow (TTM)
-1.289
Free cash flow yield (TTM)
-77.59%
Free cash flow per share (TTM)
-2.995
Growth
Revenue change (TTM)
217.44%
Earnings per share change (TTM)
-21.84%
3-year revenue growth (CAGR)
39.56%
3-year earnings per share growth (CAGR)
-16.38%
What the Analysts think about BCYC
Analyst ratings (Buy, Hold, Sell) for Bicycle Therapeutics stock.
Analyst projections of the future price of Bicycle Therapeutics stock.
BCYC Financial Performance
Revenues and expenses
BCYC Earnings Performance
Company profitability
Upcoming events
No upcoming events
BCYC News
AllArticlesVideos
Funds containing BCYC
AllUSDGBP
Fund name | Fund size | $BCYC weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.01% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.